Nasdaq · CIK 0001157601
MDGL MADRIGAL PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing 31 d ago. Close $471.75 on Oct 9, 2026, +14% from the 52-week low and -22% from the high.
Last 90 days
Net insider value
-$6.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$6.2M by 1 insider
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
MDGLOct 9, 2026 · close 471.75
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MADRIGAL PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | William John Sibold President and CEO sell | $6.2M 11,583 shares | -6% | - | |
| 40Moderate | Fred B Craves director sell | $5.1M 15,470 shares | -4% | - | |
| 26Weak | Mardi Dier SVP and CFO sell | $83k 258 shares | -2% | - | |
| 42Moderate | Mardi Dier SVP and CFO sell | $637k 1,961 shares | -22% | - | |
| 34Weak | Carole Huntsman Chief Commercial Officer sell | $598k 1,834 shares | -18% | - | |
| 21Weak | Shannon T Kelley General Counsel sell | $139k 415 shares | -5% | - | |
| 60Notable | Kenneth Bate director sell | $7.1M 20,000 shares | -91% | - | |
| 60Notable | James M Daly director sell | $5.4M 15,470 shares | -89% | - | |
| 33Weak | Carole Huntsman Chief Commercial Officer sell | $116k 347 shares | -3% | - | |
| 31Weak | Shannon T Kelley General Counsel sell | $76k 277 shares | -3% | - | |
| 53Moderate | Fred B Craves director sell | $1.1M 3,600 shares | -25% | - | |
| 53Moderate | Fred B Craves director sell | $1.2M 3,400 shares | -19% | - | |
| 42Moderate | Carole Huntsman Chief Commercial Officer sell | $218k 688 shares | -6% | - | |
| 23Weak | Richard S Levy director sell | $1.8M 5,000 shares | -31% | - | |
| 15Weak | Richard S Levy director sell | $1.5M 5,000 shares | -31% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -131 | $527.88 | $69k | 209,198 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -347 | $529.27 | $184k | 208,851 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -522 | $530.23 | $277k | 208,329 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -368 | $531.99 | $196k | 207,961 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -512 | $533.09 | $273k | 207,449 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -396 | $534.20 | $212k | 207,053 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -644 | $535.27 | $345k | 206,409 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -1,040 | $536.11 | $558k | 205,369 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -640 | $537.17 | $344k | 204,729 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -520 | $538.30 | $280k | 204,209 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -215 | $539.03 | $116k | 203,994 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -505 | $540.19 | $273k | 203,489 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -362 | $541.65 | $196k | 203,127 | 31 d ago |
| Sep 9, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -160 | $542.55 | $87k | 202,967 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -60 | $533.09 | $32k | 202,907 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -106 | $534.06 | $57k | 202,801 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -218 | $535.94 | $117k | 202,583 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -160 | $537.62 | $86k | 202,423 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -687 | $540.59 | $371k | 201,736 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -368 | $541.64 | $199k | 201,368 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -1,202 | $542.60 | $652k | 200,166 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -1,539 | $544.02 | $837k | 198,627 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -761 | $544.83 | $415k | 197,866 | 31 d ago |
| Sep 11, 2026 | William John Sibold President and CEO | SOpen-market sale Common Stock10b5-1 | -120 | $546.38 | $66k | 197,746 | 31 d ago |
| Jun 20, 2025 | Baker Bros. Advisors LP director | AGrant or award Common Stockindirect: See Footnotes | +1,430 | $0.00 | $0 | 188,837 | Jun 24, 2025 |
| Jun 20, 2025 | Kenneth Bate director | AGrant or award Common Stock | +715 | $0.00 | $0 | 2,627 | Jun 24, 2025 |
| Jun 20, 2025 | Baker Bros. Advisors LP director | AGrant or award Common Stockindirect: See Footnotes | +1,430 | $0.00 | $0 | 1,796,261 | Jun 24, 2025 |
| Jun 20, 2025 | Kenneth Bate director | AGrant or award Stock Option (Right to Buy)derivative | +1,290 | $0.00 | $0 | 1,290 | Jun 24, 2025 |
| Jun 20, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Options (right to buy)derivativeindirect: See Footnotes | +2,580 | $0.00 | $0 | 2,580 | Jun 24, 2025 |
| Jun 20, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Options (right to buy)derivativeindirect: See Footnotes | +2,580 | $0.00 | $0 | 2,580 | Jun 24, 2025 |
| Mar 12, 2025 | Fred B Craves director | MOption exercise Common Stock | +1,728 | $65.06 | $112k | 351,804 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 357,804 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -1,587 | $330.54 | $525k | 356,217 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -2,759 | $331.36 | $914k | 353,458 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -2,382 | $332.38 | $792k | 351,076 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -800 | $333.66 | $267k | 350,276 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -200 | $334.97 | $67k | 350,076 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | MOption exercise Common Stock | +7,742 | $65.06 | $504k | 357,818 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -1,951 | $322.45 | $629k | 355,867 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -1,649 | $323.47 | $533k | 354,218 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -900 | $324.69 | $292k | 353,318 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -800 | $325.63 | $261k | 352,518 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -1,000 | $327.63 | $328k | 351,518 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -400 | $328.68 | $131k | 351,118 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -967 | $329.86 | $319k | 350,151 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | SOpen-market sale Common Stock | -75 | $330.23 | $25k | 350,076 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | MOption exercise Stock Option (Right to Buy)derivative | -1,728 | $0.00 | $0 | 7,742 | Mar 14, 2025 |
| Mar 12, 2025 | Fred B Craves director | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Mar 14, 2025 |
| Mar 13, 2025 | Fred B Craves director | MOption exercise Stock Option (Right to Buy)derivative | -7,742 | $0.00 | $0 | 0 | Mar 14, 2025 |
| Mar 10, 2025 | Mardi Dier SVP and CFO | SOpen-market sale Common Stock10b5-1 | -258 | $323.04 | $83k | 10,440 | Mar 12, 2025 |
| Mar 10, 2025 | Jacqualyn A Fouse director | AGrant or award Common Stock | +894 | $0.00 | $0 | 894 | Mar 12, 2025 |
| Mar 10, 2025 | Jacqualyn A Fouse director | AGrant or award Stock Option (Right to Buy)derivative | +1,579 | $0.00 | $0 | 1,579 | Mar 12, 2025 |
| Mar 5, 2025 | Mardi Dier SVP and CFO | AGrant or award Common Stock | +3,784 | $0.00 | $0 | 10,698 | Mar 7, 2025 |
| Mar 5, 2025 | Carole Huntsman Chief Commercial Officer | AGrant or award Common Stock | +3,386 | $0.00 | $0 | 11,990 | Mar 7, 2025 |
| Mar 5, 2025 | Shannon T Kelley General Counsel | AGrant or award Common Stock | +3,187 | $0.00 | $0 | 10,477 | Mar 7, 2025 |
| Mar 5, 2025 | Mardi Dier SVP and CFO | AGrant or award Stock Option (Right to Buy)derivative | +6,374 | $0.00 | $0 | 6,374 | Mar 7, 2025 |
| Mar 5, 2025 | Carole Huntsman Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +5,703 | $0.00 | $0 | 5,703 | Mar 7, 2025 |
| Mar 5, 2025 | Shannon T Kelley General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Mar 7, 2025 |
| Mar 3, 2025 | Shannon T Kelley General Counsel | SOpen-market sale Common Stock10b5-1 | -415 | $335.00 | $139k | 7,290 | Mar 5, 2025 |
| Mar 3, 2025 | Mardi Dier SVP and CFO | SOpen-market sale Common Stock10b5-1 | -1,187 | $325.89 | $387k | 7,688 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -71 | $313.08 | $22k | 10,367 | Mar 5, 2025 |
| Mar 3, 2025 | Mardi Dier SVP and CFO | SOpen-market sale Common Stock10b5-1 | -774 | $323.54 | $250k | 6,914 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -200 | $314.74 | $63k | 10,167 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -300 | $320.21 | $96k | 9,867 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -200 | $323.65 | $65k | 9,667 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -200 | $324.59 | $65k | 9,467 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -100 | $326.34 | $33k | 9,367 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -100 | $327.49 | $33k | 9,267 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -100 | $329.64 | $33k | 9,167 | Mar 5, 2025 |
| Mar 3, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -563 | $335.00 | $189k | 8,604 | Mar 5, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 7,912 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | MOption exercise Common Stock | +9,470 | $65.06 | $616k | 11,382 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Common Stock | +9,470 | $65.06 | $616k | 17,382 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 17,382 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Common Stock | +4,530 | $9.45 | $43k | 21,912 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | SOpen-market sale Common Stock | -398 | $346.90 | $138k | 16,984 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -100 | $351.01 | $35k | 21,812 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | SOpen-market sale Common Stock | -14,302 | $347.39 | $5.0M | 2,682 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -500 | $351.99 | $176k | 21,312 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | SOpen-market sale Common Stock | -770 | $348.94 | $269k | 1,912 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -238 | $353.83 | $84k | 21,074 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | MOption exercise Stock Option (Right to Buy)derivative | -9,470 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -8,545 | $355.08 | $3.0M | 12,529 | Feb 28, 2025 |
| Feb 27, 2025 | James M Daly director | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -2,791 | $356.51 | $995k | 9,738 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -2,038 | $357.27 | $728k | 7,700 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -3,548 | $358.33 | $1.3M | 4,152 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -2,024 | $359.21 | $727k | 2,128 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | SOpen-market sale Common Stock | -216 | $360.07 | $78k | 1,912 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Stock Option (Right to Buy)derivative | -9,470 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | Kenneth Bate director | MOption exercise Stock Option (Right to Buy)derivative | -4,530 | $0.00 | $0 | 5,470 | Feb 28, 2025 |
| Jan 24, 2025 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock | -347 | $335.24 | $116k | 10,438 | Jan 27, 2025 |
| Jan 17, 2025 | Shannon T Kelley General Counsel | SOpen-market sale Common Stock | -277 | $273.41 | $76k | 7,705 | Jan 17, 2025 |
| Dec 3, 2024 | Fred B Craves director | SOpen-market sale Common Stockindirect: See Footnotes | -3,080 | $315.21 | $971k | 11,520 | Dec 5, 2024 |
| Dec 3, 2024 | Fred B Craves director | SOpen-market sale Common Stockindirect: See Footnotes | -520 | $315.90 | $164k | 11,000 | Dec 5, 2024 |
| Nov 25, 2024 | Fred B Craves director | SOpen-market sale Common Stockindirect: See Footnotes | -2,200 | $350.08 | $770k | 15,800 | Nov 27, 2024 |
| Nov 25, 2024 | Fred B Craves director | SOpen-market sale Common Stockindirect: See Footnotes | -1,200 | $350.71 | $421k | 14,600 | Nov 27, 2024 |
| Nov 21, 2024 | Carole Huntsman Chief Commercial Officer | SOpen-market sale Common Stock | -688 | $316.92 | $218k | 10,785 | Nov 22, 2024 |
| Nov 7, 2024 | Richard S Levy director | MOption exercise Common Stock10b5-1 | +5,000 | $7.36 | $37k | 16,012 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Baker Bros. Advisors LPdirector, owner
- Kenneth Batedirector
- Fred B Cravesdirector
- James M Dalydirector
- Mardi DierSVP and CFO
- Jacqualyn A Fousedirector
- Carole HuntsmanChief Commercial Officer
- Shannon T KelleyGeneral Counsel
- Richard S Levydirector
- William John SiboldPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.